More importantly, we confirmed that our GGPPS inhibitor can also induce robust antitumor efficacy in a clinically relevant mouse model of AML, using NOMO-1 xenografts in immunodeficient NSG mice. The gene discussed is GGPS1; the disease is acute myeloid leukemia.